AIM
AEGR

Acrospire Investment Management’s Aegerion Pharmaceuticals AEGR Stock Holding History

Acrospire Investment Management’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-18,800
Closed -$70K – 2439
2016
Q1 		$70K Buy
+18,800
New +$116K 0.05% 638

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Acrospire Investment Management's AEGR Position: Q2 2016 in Review

Acrospire Investment Management sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2016, closing a stake of 18,800 shares — an estimated $70K sold.

Acrospire Investment Management first reported a position in AEGR in Q1 2016 and held it in 1 quarter. The position peaked at $70K in Q1 2016. 71 funds tracked by Wall St. Rank hold AEGR as of Q2 2016.

  • Acrospire Investment Management reported no remaining Aegerion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Acrospire Investment Management sold 18,800 Aegerion Pharmaceuticals shares in Q2 2016, an estimated $70K.
  • Acrospire Investment Management first reported a position in Aegerion Pharmaceuticals in Q1 2016 and held it in 1 quarter.
  • Acrospire Investment Management's Aegerion Pharmaceuticals position peaked at $70K in Q1 2016.
  • 71 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2016.

Based on Acrospire Investment Management's 13F filing for Q2 2016, filed 9 Aug 2016.